685: Cathal Friel of Poolbeg Pharma discusses results of the proposal to purchase shares from distribution in specie shareholders

The Vox Markets Podcast

コンテンツは jruss88 and Vox Markets Podcast によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャストコンテンツは、jruss88 and Vox Markets Podcast またはそのポッドキャストプラットフォームパートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。

2y ago 4:43

MP3•エピソードのホーム

Cathal Friel Chairman of Poolbeg Pharma #POLB discusses the results of the proposal to purchase shares from distribution in specie shareholders, with 97% deciding to remain invested in the company following the end of the lock-up period.

Highlights

Poolbeg Pharma , a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces the results of the proposal from a number of New Investors to purchase shares from distribution in specie shareholders ahead of the end of the lock-up period.

As published via an RNS on 11 April 2022, the Company sourced a number of New Investors that offered to purchase up to £1.6m distribution in specie shares at a price of 5.9 pence being the closing price on 8 April 2022 (the last trading day prior to that announcement). The Company can now confirm that these proposals have been accepted by distribution in specie shareholders seeking to sell a total of £366k of Poolbeg shares, representing only 3% of the distribution in specie shares.

The vast majority, representing 97% of distribution in specie shareholders, have decided to remain invested in Poolbeg following the end of the lock-up period. Overall, the proposals have demonstrated strong shareholder confidence in the Company as it enters the exciting clinical phase of its development.

An FAQ can be found on the Company's website here.

1878 つのエピソード

#Trading #Business #Vox Markets #Need To Know